semaglutide fairfield Patient 142762751 | Before & After Gallery GLP-1 Therapy in Fairfield CT

Next-generation agents include CagriSema (semaglutide + cagrilintide, NDA filed December 2025, showing 22.7% weight loss), retatrutide (triple GIP/GLP-1/glucagon agonist, 28.7% weight loss in Phase 3), and orforglipron (oral non-peptide GLP-1, submitted to FDA)

Ilant Health founder and CEO Elina Onitskansky told Fierce Healthcare in October that some direct-to-consumer companies have different incentives that can lead to poorer health outcomes

Its status is poorly known elsewhere

Front Physiol 12:564963 Gao H, Zhao Y, Zhao L, Wang Z, Yan K, Gao B, Zhang L (2023) The role of oxidative stress in multiple exercise-regulated bone homeostasis